Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers
Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers
Active, not recruiting · NCT05205330 · Registry updated 2025-10-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, intestinal disorder, neoplasm, rectal disorder, stomach disorder | Active, not recruiting | Phase 1 / Phase 2 | 2025-10-29 | NCT05205330 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Agenus Inc. | 23 |
| Rottapharm Biotech | 1 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Azienda Ospedaliero Universitaria Pisana | Pisa | Italy | 5 |
| Istituto Nazionale dei Tumori | Milan | Italy | 2 |
| Istituto Oncologico Veneto IRCCS | Padova | Italy | 3 |